A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511837-37-00

Acronym

20200491

Enrollment

113

Registered

2024-10-09

Start date

2021-12-21

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory Small Cell Lung Cancer

Brief summary

Part 1 only - objective response (OR) (complete response [CR] and partial response [PR]) •incidence of treatment-emergent adverse events (TEAEs) •serum concentrations of Tarlatamab, Part 1 and 2 - OR (CR and PR), Part 3 - Incidence of TEAEs

Detailed description

duration of response (DOR), disease control (DC), duration of DC, progression-free survival (PFS), DOR, overall survival (OS), incidence of TEAEs, serum concentrations of Tarlatamab, incidence of anti-Tarlatamab antibody formation

Interventions

DRUGTarlatamab

DRUGTARLATAMAB

DRUGSILTUXIMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Part 1 only - objective response (OR) (complete response [CR] and partial response [PR]) •incidence of treatment-emergent adverse events (TEAEs) •serum concentrations of Tarlatamab, Part 1 and 2 - OR (CR and PR), Part 3 - Incidence of TEAEs	—

Secondary

Measure	Time frame
duration of response (DOR), disease control (DC), duration of DC, progression-free survival (PFS), DOR, overall survival (OS), incidence of TEAEs, serum concentrations of Tarlatamab, incidence of anti-Tarlatamab antibody formation	—

Countries

Austria, Belgium, Denmark, France, Germany, Greece, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026